Modimelanotide (INN) (code names AP-214, ABT-719, ZP-1480) is a melanocortinergic peptide drug derived from α-melanocyte-stimulating hormone (α-MSH) which was under development by, at different times, Action Pharma, Abbott Laboratories, AbbVie, and Zealand for the treatment of acute kidney injury.

[1][2] It acts as a non-selective melanocortin receptor agonist, with IC50 values of 2.9 nM, 1.9 nM, 3.7 nM, and 110 nM at the MC1, MC3, MC4, and MC5 receptors.

[3] Modimelanotide failed clinical trials for acute kidney injury despite showing efficacy in animal models,[4][5] and development was not further pursued.

[1][2] This drug article relating to the genito-urinary system is a stub.

You can help Wikipedia by expanding it.